Persistent Coronavirus Disease 2019 (COVID-19) in an Immunocompromised Host Treated by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific Monoclonal Antibodies

Clin Infect Dis. 2022 May 3;74(9):1706-1707. doi: 10.1093/cid/ciab868.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Viral
  • COVID-19*
  • Humans
  • Immunocompromised Host
  • SARS-CoV-2*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Viral